Technical Analysis for MRUS - Merus N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 1.58% | |
| Crossed Above 50 DMA | Bullish | 1.58% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 9 hours ago |
| 10 DMA Support | about 12 hours ago |
| 20 DMA Support | about 12 hours ago |
| 50 DMA Support | about 12 hours ago |
| Gap Up Closed | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/01/2023
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 27.7 |
| 52 Week Low | 12.05 |
| Average Volume | 282,213 |
| 200-Day Moving Average | 20.70 |
| 50-Day Moving Average | 23.73 |
| 20-Day Moving Average | 23.89 |
| 10-Day Moving Average | 24.16 |
| Average True Range | 1.43 |
| RSI (14) | 55.16 |
| ADX | 17.23 |
| +DI | 30.08 |
| -DI | 17.97 |
| Chandelier Exit (Long, 3 ATRs) | 22.99 |
| Chandelier Exit (Short, 3 ATRs) | 25.65 |
| Upper Bollinger Bands | 25.51 |
| Lower Bollinger Band | 22.28 |
| Percent B (%b) | 0.68 |
| BandWidth | 13.52 |
| MACD Line | 0.18 |
| MACD Signal Line | 0.20 |
| MACD Histogram | -0.0164 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 29.92 | ||||
| Resistance 3 (R3) | 30.24 | 28.76 | 29.01 | ||
| Resistance 2 (R2) | 28.76 | 27.37 | 28.59 | 28.70 | |
| Resistance 1 (R1) | 26.61 | 26.51 | 25.87 | 26.29 | 28.40 |
| Pivot Point | 25.13 | 25.13 | 24.76 | 24.96 | 25.13 |
| Support 1 (S1) | 22.98 | 23.74 | 22.24 | 22.66 | 20.54 |
| Support 2 (S2) | 21.50 | 22.88 | 21.33 | 20.24 | |
| Support 3 (S3) | 19.35 | 21.50 | 19.93 | ||
| Support 4 (S4) | 19.03 |
